Alnylam Pharmaceuticals (ALNY) Shares are Down -10.31%

Alnylam Pharmaceuticals (ALNY) : During the past 4 weeks, traders have been relatively bearish on Alnylam Pharmaceuticals (ALNY), hence the stock is down -1.48% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -10.46% relative to the S&P 500. The 4-week change in the price of the stock is -2.01% and the stock has fallen -10.31% in the past 1 week.

The stock has recorded a 20-day Moving Average of 8.45% and the 50-Day Moving Average is 6.64%.The 200 Day SMA reached 0.5%


Alnylam Pharmaceuticals (NASDAQ:ALNY): The stock opened in the green at $70.26 on Friday, but the bulls found it difficult to push the prices higher. The stock reached a high of $70.38 and a low of $67.06 for the day. The stock did not find buyers even at the lows and closed at $67.78 recording a loss of -3.09%. 857,140 shares exchanged hands during the trading day. The stock had closed at $67.78 in the previous days trading.

Alnylam Pharmaceuticals (ALNY) : Average target price received by Alnylam Pharmaceuticals (ALNY) is $109.1 with an expected standard deviation of $33.51. The most aggressive target on the stock is $180, whereas the most downbeat target is $74. 10 financial analysts are currently covering the stock.

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics based on its ribonucleic acid interference (RNAi). The Companys pipeline focuses in three strategic therapeutic areas (STArs): Genetic Medicines, with a pipeline of RNAi therapeutics for the treatment of rare diseases; Cardio-Metabolic Disease, with a pipeline of RNAi therapeutics toward genetically validated, liver-expressed disease in cardiovascular and metabolic diseases, and hepatic infectious disease, with a pipeline of RNAi therapeutics for treatment of hepatic infectious diseases. Its products include Patisiran (ALN-TTR02), Revusiran (ALN-TTRsc), ALN-AT3, ALN-CC5, ALN-AS1, ALN-AAT, ALN-GO1, ALN-TMP, ALN-PCS, ALN-PCSsc, ALN-AC3, ALN-ANG, ANGPTL3, ALN-HBV, ALN-HDV and ALN-PDL. The Company is developing two investigational RNAi therapeutic candidates for TTR-Mediated Amyloidosis (ATTR): patisiran and revusiran.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.